AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Candidate Receives IND Approval from China's CDE

Stock News06-23

AB&B BIO-TECH-B (ASX: 02627) has announced that, following the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation (CDE) of China's National Medical Products Administration has also approved the IND application for the company's self-developed mRNA monkeypox vaccine candidate. The approval was granted on June 21, 2026.

Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. This genus includes a wide range of viruses, such as vaccinia virus, variola virus (smallpox), and mousepox virus.

In preclinical studies, the company's investigational mRNA monkeypox vaccine candidate elicited significantly higher levels of monkeypox-neutralizing antibodies compared to the attenuated live smallpox vaccine strain (Tiantan strain) used in China. Furthermore, it demonstrated broad-spectrum cross-reactivity against multiple Orthopoxvirus antigens.

When compared to internationally licensed replication-deficient monkeypox vaccines, the company's mRNA vaccine candidate has shown superior immunogenicity. This profile makes it a potentially more suitable option for immunocompromised individuals, such as those who are HIV-positive.

This vaccine candidate is reported to be the first mRNA-based monkeypox vaccine candidate globally to have its IND application approved by both the U.S. FDA and China's CDE.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121897103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121897103","market":"sh","top_or_hot":-1,"title":"AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Candidate Receives IND Approval from China's CDE","media":"Stock News","content":"<p><b>AB&B BIO-TECH-B</b> (<b>ASX: 02627</b>) has announced that, following the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation (CDE) of China's National Medical Products Administration has also approved the IND application for the company's self-developed mRNA monkeypox vaccine candidate. The approval was granted on June 21, 2026.<br><br>Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. This genus includes a wide range of viruses, such as vaccinia virus, variola virus (smallpox), and mousepox virus.<br><br>In preclinical studies, the company's investigational mRNA monkeypox vaccine candidate elicited significantly higher levels of monkeypox-neutralizing antibodies compared to the attenuated live smallpox vaccine strain (Tiantan strain) used in China. Furthermore, it demonstrated broad-spectrum cross-reactivity against multiple Orthopoxvirus antigens.<br><br>When compared to internationally licensed replication-deficient monkeypox vaccines, the company's mRNA vaccine candidate has shown superior immunogenicity. This profile makes it a potentially more suitable option for immunocompromised individuals, such as those who are HIV-positive.<br><br>This vaccine candidate is reported to be the first mRNA-based monkeypox vaccine candidate globally to have its IND application approved by both the U.S. FDA and China's CDE.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Candidate Receives IND Approval from China's CDE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B BIO-TECH-B's mRNA Monkeypox Vaccine Candidate Receives IND Approval from China's CDE\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-23 18:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>AB&B BIO-TECH-B</b> (<b>ASX: 02627</b>) has announced that, following the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation (CDE) of China's National Medical Products Administration has also approved the IND application for the company's self-developed mRNA monkeypox vaccine candidate. The approval was granted on June 21, 2026.<br><br>Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. This genus includes a wide range of viruses, such as vaccinia virus, variola virus (smallpox), and mousepox virus.<br><br>In preclinical studies, the company's investigational mRNA monkeypox vaccine candidate elicited significantly higher levels of monkeypox-neutralizing antibodies compared to the attenuated live smallpox vaccine strain (Tiantan strain) used in China. Furthermore, it demonstrated broad-spectrum cross-reactivity against multiple Orthopoxvirus antigens.<br><br>When compared to internationally licensed replication-deficient monkeypox vaccines, the company's mRNA vaccine candidate has shown superior immunogenicity. This profile makes it a potentially more suitable option for immunocompromised individuals, such as those who are HIV-positive.<br><br>This vaccine candidate is reported to be the first mRNA-based monkeypox vaccine candidate globally to have its IND application approved by both the U.S. FDA and China's CDE.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1121897103","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121897103","pubTimestamp":1782209561,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"AB&B BIO-TECH-B (ASX: 02627) has announced that, following the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), the Center for Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","BK1161":"生物科技","02627":"中慧生物-B","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"AB&B BIO-TECH-B的mRNA猴痘候选疫苗获得中国CDE的IND批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"02627":1,"IND":1},"content_text":"AB&B BIO-TECH-B (ASX: 02627) has announced that, following the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation (CDE) of China's National Medical Products Administration has also approved the IND application for the company's self-developed mRNA monkeypox vaccine candidate. The approval was granted on June 21, 2026.Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. This genus includes a wide range of viruses, such as vaccinia virus, variola virus (smallpox), and mousepox virus.In preclinical studies, the company's investigational mRNA monkeypox vaccine candidate elicited significantly higher levels of monkeypox-neutralizing antibodies compared to the attenuated live smallpox vaccine strain (Tiantan strain) used in China. Furthermore, it demonstrated broad-spectrum cross-reactivity against multiple Orthopoxvirus antigens.When compared to internationally licensed replication-deficient monkeypox vaccines, the company's mRNA vaccine candidate has shown superior immunogenicity. This profile makes it a potentially more suitable option for immunocompromised individuals, such as those who are HIV-positive.This vaccine candidate is reported to be the first mRNA-based monkeypox vaccine candidate globally to have its IND application approved by both the U.S. FDA and China's CDE.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121897103","isCrawlerRequest":true}